Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05229445 · ClinicalTrials.gov registry record · NA

A Continuous Glucose Monitor Based Insulin Bolus Calculator

A NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, sponsored by Welldoc.

Completed
Registry status
NA
Development phase
27
Enrollment target
1
Study location

NCT05229445 is a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1 that has completed, run by Welldoc. The registered enrollment target is 27 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05229445, a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, Type 1, has completed, sponsored by Welldoc.

COMPLETED
Registry status
NA
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor

Interventions

  • DEVICE continuous glucose monitor based insulin bolus calculator

Study Locations (1)

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2022-07-05
Est. Completion 2022-09-28
Phase NA

Sponsor

Welldoc

2 total trials

What the Registry Record Tells You About NCT05229445

The ClinicalTrials.gov registry entry for NCT05229445 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is Welldoc, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which continuous glucose monitor based insulin bolus calculator is the first listed.

NCT05229445 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05229445 about?

NCT05229445 is a clinical study titled "A Continuous Glucose Monitor Based Insulin Bolus Calculator". This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor

What is the current status of trial NCT05229445?

This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2022-07-05. Estimated completion is 2022-09-28.

What conditions does trial NCT05229445 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1.

What interventions are being tested in trial NCT05229445?

The interventions under investigation include: continuous glucose monitor based insulin bolus calculator (DEVICE).

Who is sponsoring clinical trial NCT05229445?

This trial is sponsored by Welldoc, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05229445 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.